anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The proposed study is an exploratory trial to evaluate the use of aromatherapy for symptom management in patients undergoing chemotherapy. The investigators will accrue 120 adult cancer subjects undergoing chemotherapy in a initial efficacy study to determine the effectiveness of three different aromatherapies (ginger, lavender, or orange) on chemotherapy-related symptoms (nausea, vomiting, pain, anxiety, sleep difficulties, fatigue, and lack of appetite) compared to placebo (i.e., jojoba). All subjects will be randomized to one of the four arms for symptom management during three different chemotherapy cycles. The investigators will examine the incidence and severity of the seven symptoms at each chemotherapy cycle. The preliminary data from this study will elucidate the relationships between certain aromatherapies and specific symptom relief, which can be further evaluated in a larger confirmatory study of subjects undergoing chemotherapy or other types of cancer treatment. This study will provide clinical evidence regarding the incorporation of aromatherapy into cancer patient care.
A composition and method for stimulating an immune response against an antigen in immunised individuals or in cell groups. The composition comprises a protein called Lip2a Leishmania formed by a sequence of amino acids coded for by a sequence of DNA that comprises the nucleotides: 1-1 of nos. 778 to 1231 of SEQ. ID NO ! 1-2 or formed by a sequence of nucleotides able to hybridise with the sequence described in 1-1 under moderately strict hybridisation conditions and which would therefore code for a protein similar to Lip2a. The method comprises incubating said cells with said Lip2a protein in the presence or not of an antigen specific to a disease or infection.
Tocilizumab 8 mg/kg intravenous (IV) every 4 weeks + Placebo to adalimumab subcutaneous (SC) every 2 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 20 weeks.
Systems and methods are provided for adjusting a basal/bolus ratio in a standing insulin regimen for a subject that comprises daily amounts of basal and bolus insulin medicaments that define an initial basal/bolus ratio. A data set comprising glucose measurements of the subject with a respective timestamp for each such measurement over a time course is obtained. One or more fasting events are identified in the time course. A temporal glucose gradient is computed for each fasting event using the glucose measurements in the data set within the fasting event time period. Fasting event glucose gradients are used to determine whether to recommend adjustment to the basal/bolus ratio for the subject without change to the daily total insulin medicament. The recommended adjustment to the basal/bolus ratio is communicated when the determination is made to make the recommended adjustment to the basal/bolus ratio for the subject.
The system has a reading unit (11) reading identification information contained in a radio frequency identification (RFID) type electronic identification unit (10) i.e. electronic chip. A measuring unit (12) measures physical data associated to a pet animal. A storage and/or transmission unit (13) stores and/or transmits the data. The measuring unit is provided with a weighing machine. The reading unit is integrated with the machine. The transmission unit cooperates with a connection permitting transfer of the data towards an external unit e.g. personal digital assistant (PDA).
A delivery device for delivering an active substance (10) after a predetermined time delay (e.g. 0.5 to 12 hrs) after administration to a patient, comprises a hollow female body (6) having a plug (2) formed of a hydrogel material in the neck thereof. The plug swells in contact with an aqueous medium (e.g. gastrointestinal fluid) and disengages at the predetermined time. An excipient (12) whose volume expands in contact with the aqueous medium is provided in the body to quickly and completely expel the active substance from the body into the aqueous medium after disengagement of the plug. The expandible excipient is a material which generates a gas in contact with aqueous medium, such as a mixture of a carbonate or bicarbonate and an acid.
The study is a randomized, double-blind, placebo controlled, multi-center trial. We aim to enroll a total of 1968 individuals(984 cases in each group) with acute ischemic stroke less than 72 hours after onset. Participants will be randomized into Tongxinluo capsule treatment group with the capsule administration of 4 granules tid. for 90 days, while the patients in the control group receive placebo capsule. NIH Stroke Score of the subjects is 4-22 at randomization. Evaluations of efficacy and safety will be taken at baseline, 7 days, discharge date and 90 days. Neuroimaging \[magnetic resonance imaging (MRI) scans\] will be obtained at baseline and 90 days after therapy. The primary efficacy endpoint is the proportion of Modified Rankin Scale (mRS) ≤1 at 90 days.
The invention disclosed is a method and instrument set for repairing focal arthritic defects in a mammalian joint, especially in a human knee. The articular cartilage transplantation instrument set includes a coring device and first and second obturators. The coring device includes a cylindrical tube extending a distance along a coring axis between distal and proximal ends. A set of cutting elements or teeth are disposed at the distal end, and a gripper is at the proximal end. The outer diameters of the obturators are slightly less than the inner diameter of the tube of the coring device so that each of the obturators may be slidingly within the tube of the device with each of the respective obturator axes being substantially coaxial with the axis of the of the coring device tube. The length of the first obturator is selected so that when its rod is positioned all the way into the tube of the device, the distal end of the obturator is displaced by a distance X1 from the distal end of the device. The length of the second obturator is selected so that when the second obturator is fully positioned within the device 12, the end of the second obturator is substantially at (or extends beyond) the distal end of the device 12.
The invention relates to a tamsulosin hydrochloride film-controlled slow-release pellet capsule. A slow-release film of the tamsulosin hydrochloride film-controlled slow-release pellet utilizes Eurdragit NE30D and HPMC E5 as film-formation materials. A pellet core of the tamsulosin hydrochloride film-controlled slow-release pellet contains sodium carboxymethyl starch having high expansibility, and also contains pharmaceutically-acceptable common excipients for the slow-release pellet, wherein preferably, the excipients comprise microcrystalline cellulose and lactose as fillers, and polysorbate 80 as a solubilizer; and the pellet core comprises 5 to 20wt% of sodium carboxymethyl starch. The slow-release film comprises Eurdragit NE30D, HPMC E5 and talcum powder as an antiplastering aid, wherein preferably, a ratio of Eurdragit NE30D to HPMC E5 to talcum powder is 30: 2: 4 and a film weight increasing ratio is in a range of 19 to 36%. The tamsulosin hydrochloride film-controlled slow-release pellet comprises the pellet core containing sodium carboxymethyl starch having high water expansibility and thus after absorbing water, the tamsulosin hydrochloride film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the tamsulosin hydrochloride film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.
Participants received placebo dosed BID orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
BACKGROUND: There is a lack of predictive biomarkers for the onset or activity of protein-losing enteropathy (PLE), a Fontan procedure-associated complication. Here, we aimed to identify the gut microbiota composition of patients with active PLE and investigate its relationship with PLE activity.
METHODS: This multicenter case-control study involved patients who developed PLE (n = 16) after the Fontan procedure and those who did not (non-PLE; n = 20). Patients with PLE who maintained a serum albumin level of ≥3 g/dL for >1 year were included in the remissive-stage-PLE group (n = 9) and those who did not maintain this level were included in the active-PLE group (n = 7). 16S rRNA gene sequencing analysis of fecal samples was performed using QIIME2 pipeline. Alpha (Shannon and Faith's phylogenetic diversity indices) and beta diversity was assessed using principal coordinate analysis based on unweighted UniFrac distances.
RESULTS: Shannon and Faith's phylogenetic diversity indices were lower in the active-PLE group than in the remissive-stage- (q = 0.028 and 0.025, respectively) and non-PLE (q = 0.028 and 0.017, respectively) groups. Analysis of beta diversity revealed a difference in the microbiota composition between the active-PLE and the other two groups. Linear discriminant effect size analysis demonstrated differences in the relative abundance of Bifidobacterium and Granulicatella spp., and Ruminococcus torques between patients with active- and those with remissive-stage-PLE.
CONCLUSIONS: Gut microbiota dysbiosis was observed in patients with active PLE. Changes in the bacterial composition of the gut microbiota and decreased diversity may be associated with the severity of PLE.
In this study, the investigators are attempting to determine whether compounded topical pain creams are more effective than placebo; as well as measuring the subjects' satisfaction with the compounded pain creams. Three different compounded pain creams (specific to the type of pain being treated) will be used to examine effectiveness and satisfaction in treating neuropathic, nociceptive, or mixed pain syndromes. Up to 399 subjects will be randomized to receive a compounded pain cream or placebo. The type of pain cream to be used will be based on the subjects' pain diagnosis. Pain relief will be measured by a 0-10 Numeric Rating Scale and satisfaction by a 1-5 Likert Satisfaction Scale. The outcome measures will include a 'positive outcome' defined as a two point or greater reduction in average pain (as measured by a NRS) and a score of greater than 3 (on a 1-5 Likert scale measuring satisfaction) at 1-month. The investigators will use the Rand Corporation SF-36 to measure changes in health status during enrollment. Subjects who obtain benefit at 1-month will be followed at 3-months, while those who fail to obtain benefit (i.e., ≥ 2 point reduction in NRS with a greater than 3 Likert satisfaction score) will exit the study to receive alternative care. Patients will be given a pain diary so that their NRS can be calculated at follow up visits.
### Teratogenic Effects

#### Pregnancy Category C

In studies conducted in rats and rabbits, bupropion was administered orally at doses up to 450 and 150 mg/kg/day, respectively (approximately 11 and 7 times the maximum recommended human dose [MRHD], respectively, on a mg/m2 basis), during the period of organogenesis. No clear evidence of teratogenic activity was found in either species; however, in rabbits, slightly increased incidences of fetal malformations and skeletal variations were observed at the lowest dose tested (25 mg/kg/day, approximately equal to the MRHD on a mg/m2 basis) and greater. Decreased fetal weights were seen at 50 mg/kg and greater.

When rats were administered bupropion at oral doses of up to 300 mg/kg/day (approximately 7 times the MRHD on a mg/m2 basis) prior to mating and throughout pregnancy and lactation, there were no apparent adverse effects on offspring development.

One study has been conducted in pregnant women. This retrospective, managed-care database study assessed the risk of congenital malformations overall and cardiovascular malformations specifically, following exposure to bupropion in the first trimester compared to the risk of these malformations following exposure to other antidepressants in the first trimester and bupropion outside of the first trimester. This study included 7,005 infants with antidepressant exposure during pregnancy, 1,213 of whom were exposed to bupropion in the first trimester. The study showed no greater risk for congenital malformations overall or cardiovascular malformations specifically, following first trimester bupropion exposure compared to exposure to all other antidepressants in the first trimester, or bupropion outside of the first trimester. The results of this study have not been corroborated. Bupropion hydrochloride tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
The invention relates to a traditional Chinese medicine for treating swine fever and a preparation method thereof. The traditional Chinese medicine comprises following traditional Chinese medicine raw materials in parts by weight: cordate houttuynia, sweet wormwood, isatis root, dandelion, reed rhizome, honeysuckle flower, radix scutellariae, fructus forsythiae, patrinia herb, coix seed, Chinese yam, balloonflower root, grosvenor momordica fruit, belamcanda rhizome, earthworm, radix scrophulariae, dried rehmannia root, dried orange peel, oldenlandia diffusa and motherwort. The traditional Chinese medicine is prepared by reasonable compatibility, and by steps of sterilizing, drying, smashing, cleaning, dipping, decocting for the first time, decocting for a second time, mixing, concentrating, drying and combining. The traditional Chinese medicine has an antiviral function and functions of clearing away heat, detoxifying, relieving cough, relieving asthma, eliminating phlegm, and the like, and has good curative effects for pneumonia, enteritis, tonsillitis, conjunctivitis, and the like which are caused by viruses. The traditional Chinese medicine overcomes a reproductive disturbance problem of sicken sows. The curative rate of the traditional Chinese medicine for acute and chronic swine fever can be higher than 95%. Long-term taking of the traditional Chinese medicine can boost body immunity of pigs. The traditional Chinese medicine avoids medicine residue, guarantees the pork quality, and prevents the swine fever.
Patients with headache \> 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
Patients with limited-stage SCLC receive etoposide and cisplatin (carboplatin) induction therapy for 2 cycles and then receive thoracic radiotherapy (45 Gy/30 fractions) with concurrent EP/EC chemotherapy for 2cycles, the CTVs of the tumor in lung parenchyma are omitted. Patients who achieve CR or PR then receive prophylactic cranial irradiation (PCI, 25 Gy/10 fractions).
The present invention relates to a process for preparing antalgic thermotherapeutic medicine, which comprises (1), an ointment preparing process, (2), a hot bag preparing process and (3), a product molding process. The present invention has the advantages of simple process and large preparing yield, and prepares antalgic thermotherapeutic medicine by large scale in flow lines. The present invention has high efficiency, and satisfies the requirements of wide patients. The antalgic thermotherapeutic medicine prepared by the present invention has thin and small volume, long heating time, high thermal speed and stable temperature, and constant time can achieve about 15 hours from 42 to 55 DEG C. The process has portability and convenient use. The medicine of a medicine sheet layer is super fine powder. Therefore, after the antalgic thermotherapeutic medicine heats, the medicine has good permeability. Because of long heating time of moxibustion, stable temperature and good medicine permeability, an antalgic curative effect is obvious and the pain of the patients is relieved rapidly.
Patients will undergo leukapheresis of peripheral blood for further T cell enrichment; activation and genetic modification using a lentiviral vector encoding a GPRC5D targeted CAR (MCARH109). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. These modified T cell infusions will be administered 2-7 days following completion of conditioning chemotherapy.
ABP 959 is a biosimilar to the eculizumab reference product (RP), which is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). This multicenter, randomized, double-blind, active-controlled, two-period crossover study randomized eculizumab RP-treated patients with PNH to one of two treatment sequences (ABP 959/eculizumab RP or eculizumab RP/ABP 959) to evaluate the clinical similarity of ABP 959 when compared with eculizumab RP. This study evaluated the efficacy of ABP 959 when compared with eculizumab RP based on control of intravascular hemolysis as measured by lactate dehydrogenase (LDH) and by the time-adjusted area under the effect curve of LDH. Secondary outcomes included safety, pharmacokinetics, and immunogenicity. Forty-two patients were randomized (20 in the ABP 959/eculizumab RP group and 22 in the eculizumab RP/ABP 959 group) across 25 centers. Similarity of efficacy was established by a ratio of geometric least squares means of LDH (ABP 959/eculizumab RP) of 1.0628, with a one-sided 97.5% upper CI of 1.1576 at week 27, and a geometric means ratio of time-adjusted area under the effect curve (ABP 959 vs. eculizumab RP) of LDH of 0.981, with a 90% CI of 0.9403-1.0239 from week 13 to 27, week 39 to 53, and week 65 to 79. All secondary efficacy endpoints were comparable between treatment groups. No new safety concerns were identified. The results of this study in patients with PNH, along with previously demonstrated similarity of analytical, nonclinical, and clinical pharmacokinetics and pharmacodynamics in healthy volunteers support a demonstration of no clinically meaningful differences between ABP 959 and eculizumab RP. Clinical Trial Registration: NCT03818607.
Women living with HIV/AIDS (WLHA) bear HIV stigma layered with gender disparity. They continue to suffer from internalized shame, which compromises their mental health and discourages them from seeking healthcare. Stigma among WLHA has the most detrimental impact on WLHA in Asian Countries, such as Vietnam, due to the deeply rooted male supremacy in the culture. The objective of this study is to investigate Vietnamese WLHA's cognitive, emotional, and behavioral responses to stigma, and test strategies to address the adverse impact of stigma on WLHA's health and service seeking. This proposed 2-year study, which will be conducted in Hanoi, Vietnam, will proceed in two phases.

In Phase 1, we will conduct formative studies, including in-depth interviews with 30 WLHA, one focus group with 10 healthcare providers, and one focus group with 10 community stakeholders. The aim of the formative study is to explore the cultural and contextual background of HIV stigma and gender disparity in Vietnam, investigate WLHA's barriers to access healthcare, identify locally available resources to combat stigma, and solicit feedback on some of the potential stigma-reduction intervention strategies. Phase 1 findings will inform the strategies to be pilot tested in Phase 2.

In Phase 2, the intervention will be piloted among 90 WLHA. The WLHA participants will be recruited from HIV testing sites, HIV outpatient clinics, obstetrics/maternity clinics, community-based organizations, and women's associations in Hanoi. The pilot testing period will be approximately six months. During the first month (Month 1), the WLHA will attend a group session to build initial contact with each other and prepare for the following online activities. During the preparation session, online support groups will be established using popular local socializing applications (e.g., Facebook). There will be approximately 30 WLHA in each online group. During the following three months (Month 2-4), study investigators will deliver stigma reduction intervention in the online groups, with focuses to address cognitive process of societal stigma, adjust negative emotional responses to stigma, and promote positive coping and active services seeking. During the final two months (Month 5-6), WLHA will continue the discussion and mutual support activities in the online groups without the intervention of study investigators. The online discussions will serve as process data to inform the usability and sustainability of the intervention. WLHA participants will be surveyed at baseline, 4-, and 6-month to assess their cognitive, emotional, behavioral responses to stigma, perceived social support, service utilization, and physical/mental health. In addition, final focus groups will be organized with participating WLHA to collect feasibility/acceptability evaluations and feedback for intervention components. The information will be used to refine the intervention and its implementation plan.
A system and method of providing customized hair care information including the step of gathering data on an individual's hair. The system and method includes the step of creating, within a computerized system, an account. The system and method includes storing the gathered data in association with the account in a computerized data storage device. The system and method include the step of analyzing the stored data using a processor in association with a computerized knowledge base thereby generating account analytics. The step of analyzing stored data from a plurality of diverse accounts includes the step of grouping the analyzed stored data by at least one category selected from the group of categories consisting of: race/ethnicity, hair color, hair composition, hair style, hair length, hair thickness, and hair curliness. The system and method includes automatically generating a customized hair report based on the account analytics.